natgillin/translations-raw huggingface dataset:
at least one collecting line coupled between said at least one mobile suction means and said at least one filtration means; 
filtriranje protoka usisanog mobilnim sredstvom za usisavanje (5), najmanje jednim sredstvom za filtriranje (3); i povratak filtrirane vode u navedeno najmanje jedno sredstvo spremanja (8);
a first initial path, wherein a maximum amplitude from a current position to an extreme position in an opposite direction, a certain percentage of the maximum velocity of the movement, and a certain percentage of a maximum acceleration of said stabilizing fin are used; and 
- < prve početne putanje, gdje se koristi najveća amplituda od trenutnog položaja do krajnjeg položaja u suprotnom smjeru, određeni postotak maksimalne brzine kretanja, te određeni postotak maksimalnog ubrzanja navedene stabilizirajuće peraje (200); i/ili
Process for obtaining optically active pirlindole enantiomers, in the form of a free base or in the form of a pharmaceutically acceptable salt characterized by carrying out a resolution by crystallization with optically active acids of (rac)-pirlindole in the free base form, wherein such process comprises the isolation of (rac)-pirlindole in the free base form, dissolving it in an organic solvent selected from the group consisting of: methanol, ethanol, propanol, 1-butanol, 2-butanol, tert-butyl alcohol, 2-butanone, acetone, ethyl methyl ketone, methyl isobutyl ketone, dimethylsulfoxide, 1,2-dichloroethane, diethyl ether, dimethyl ether, dimethylformamide, methyl tert-butyl ether, 2-propanol, pyridine, toluene, xylene or mixtures thereof in any proportion, adding the optically active acid and stirring the suspension from 15 minutes to 2 hours as well as using an organic solvent selected from the same group in the purification. 
Proces dobivanja optički aktivnih enantiomera pirlindola, u obliku slobodne baze ili u obliku farmaceutski prihvatljive soli naznačen izvođenjem rezolucije kristalizacijom sa optički aktivnim kiselinama (rac)-pirlindola u obliku slobodne baze, gdje takav process obuhvaća izolaciju (rac)-pirlindola u obliku slobodne baze, njegovo otapanja u organskom otapalu koji je odabran iz grupe koja se sastoji od: metanola, etanola, propanola, 1-butanola, 2-butanola, terc-butil alkohola, 2-butanona, acetona, etil metil ketona, metil izobutil ketona, dimetilsulfoksida, 1,2-dikloroetana, dietil etera, dimetil etera, dimetilformamida, metil terc-butil etera, 2-propanola, piridina, toluena, ksilena ili njihovih smjesa u bilo kojoj proporciji, dodavanje optički aktivne kiseline i miješanje suspenzije od 15 minuta do 2 sata kao i korištenje organskog otapala koji je odabran iz iste grupe u pročišćavanju.
The organics are combined, dried (Na2SO4) and evaporated in vacuo. 
Organski dio se sjedini, osuši (NaoSOx) i ispari u vakuumu.
The monoclonal antibody of claim 19 for use in improving outcomes in orthopedic procedures, dental procedures, implant surgery, joint replacement, bone grafting, bone cosmetic surgery or bone repair such as fracture healing, nonunion healing, delayed union healing or facial reconstruction. 
Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 10 do 17, naznačeno time, da se koristi u postupku poboljšanja ishoda kod ortopedskih zahvata, dentalnih zahvata, operacija usadka, zamjene zgloba, presađivanja kosti, kozmetičke operacije kosti i reparacije poput liječenja lomova, zacjeljivanja bez srastanja, zakašnjelog zacjeljivanja bez srastanja ili rekonstrukcije lica.
A device according to one of claims 1 to 6, characterized in that said irregularities or engravings in said body are filled up with a magnetic material. 
Uređaj sukladno jednom od patentnih zahtjeva 1 do 4, naznačen time, da su navedene gravure u navedenom tijelu ispunjene magnetskim materijalom.
A modulator according to the formula in claim 1 for use, characterized in that it has effect on mutant CFTR protein, wherein said CFTR mutation is a mutation AF508-CFTR, or another mutation of class II. 
Modulator formule (I) u skladu s patentnim zahtjevom 1, za uporabu u liječenju cistične fibroze pri čemu on ima učinak na mutirani CFTR protein, pri čemu je navedena mutacija CFTR mutacija ∆F508-CFTR, ili druga mutacije klase II.
a sugar alcohol; and 
(B)šećerni alkohol; i
the population contains no more than 1 EU of endotoxin per milligram of ApoA-I; 
populacija sadrži ne više od 1 EU, ne više od 0.5 EU, ne više od 0.3 EU ili ne više od 0.1 EU endotoksina po miligramu ApoA-I;
dC or dT for use according to claim 20, wherein the adverse effect is chosen from the group consisting of diarrhea and abdominal bloating. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 19, naznačen time što se štetni učinak bira iz skupine koju čine proljev i nadutost u trbuhu.
Example 1: Restoration of the pentameric gH complex 
Broj objave europskog patenta:
is the 5-6 membered heterocyclic ring: and X2 are, independently, a bond or C1-7 alkyl, and 
X, i X, su, neovisno, veza ili C,.7 alkil, a D je veza ili Ci; alkil.
Another aspect of the invention relates to a pharmaceutical composition comprising the bacterial species Roseburia hominis and a pharmaceutically acceptable excipient, carrier or diluent. 
Farmaceutski sastav koji sadrži bakterijsku vrstu Roseburia hominis i farmaceutski prihvatljiv ekscipijens, nosač ili diluent.
A pharmaceutical composition comprising the immunoconjugates of any one of clauses 31-45, wherein the immunoconjugates have an average of about 3 to about 4 (C) per (A). The pharmaceutical composition of clause 41, wherein the immunoconjugates have an average of about 3.5 (C) per (A). 
Farmaceutska kompozicija koja sadrži imunokonjugat iz bilo kojeg od patentnih zahtjeva 7-15, gdje imunokonjugat ima prosjek od oko 3 do oko 4 (C) po (A) ili prosjek od oko 3.5 (C) po (A).
In vitro release of the active ingredient from the preparation was determined in a paddle stirrer apparatus in accordance with Pharm. Eur. 
Oslobađanje in-vitro djelatne tvari iz tablete određeno je u spravi za miješanje s velikom lopaticom (Blattriihrerapparatur) prema Europskoj farmakopeji.
B is (CH2)n where n is an integer from 0 to 10; or an unsaturated carbon chain of 2 to 10 carbons; and 
B je (CH>), gdje je n cijeli broj u rasponu od 0-10, ili je B nezasićemi lanac ugljika s 2-10 ugljika; i
Many of the starting materials of the formula (II) in which Q is benzyl are described and claimed in our European patent application publication no. 
Mnogi od polaznih materijala formule (II) u kojoj je Q benzil, opisana su i zaštićena u našoj Europskoj patentnoj prijavi No.
The method according to claim 7, (I) wherein the methylene diphenyl diisocyanate is mixed with the coating composition containing a binder and is then applied to the surface of the expanded polystyrene particles, or is separately applied before or after application of the coating composition; or 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što metilen-difenil-diizocijanat se pomiješa s pokrovnom smjesom koja sadrži vezivo, te primijeni na površinu čestica ekspandiranog polistirena, ili se primijeni odvojeno, prije ili nakon primjene pokrovne smjese; ili
The inducing substrate is free of any sugar other than the constituents listed above. Thus, the relative proportions of each of the constituents are selected such that the sum of the quantities by weight is equal to 100%. 
* 10% do 39% masenih ksiloze; te je zbroj navedenih sastojaka jednak 100%, i mikroorganizam pripada vrsti Trichoderma reesei i briše se radi katabolitičke represije s glukozom.
A compound of formula I: or a pharmaceutically acceptable salt, or solvate thereof. 
Vanna Q ča ili njegova farmaceutski prihvatljiva sol, ili solvat od toga.
The fusion protein of claim 1, wherein the binding protein is selected from the group consisting of an antibody, a divalent antibody fragment, a monovalent antibody fragment, or a proteinaceous binding molecule with antibody-like binding properties. The fusion protein of claim 2, wherein the binding protein is modified such that it has an enhanced antibody dependent cellular cytotoxicity (ADCC)-activity compared to the unmodified binding protein. The fusion protein of any of claims 1-3, wherein the target cell expresses a tumor associated antigen (TAA) and/or an antigen associated with autoimmune diseases. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što se proteinski vežuću molekulu sa svojstvima vezanja kao kod protutijela bira iz skupine koju čine aptamer, mutein na bazi polipeptida iz lipokalinske porodice, aglutinirajuće tijelo, protein na bazi ankirinske okosnice, protein na bazi kristalinske okosnice, adnektin, avimer ili (rekombinantni) receptorski protein. Fuzijski protein u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je vežući protein tako modificiran da ima povećanu aktivnost stanične citotoksičnosti (ADCC) ovisnu o protutijelu u usporedbi s istim, no nemodificiranim vežućim proteinom, gdje modificirani vežući protein može biti optimiziran u Fc i/ili gdje modificirani vežući protein može biti protutijelo, scFv-Fc fragment, bsFc-1/2 dimer ili bsFc-CH3-1/2 dimer.
a heavy chain variable region CDR1 of SEQ ID NO: 2; a heavy chain variable region CDR2 of SEQ ID NO: 9; a heavy chain variable region CDR3 of SEQ ID NO: 16; a light chain variable region CDR1 of SEQ ID NO: 23; a light chain variable region CDR2 of SEQ ID NO: 30; and a light chain variable region CDR3 of SEQ ID NO: 37; or 
(a) CDRI varijabilno područje jakog lanca od SEQ ID NO:2; CDR2 varijabilno područje jakog lanca od SEQ ID NO:9; CDR3 varijabilno područje jakog lanca od SEQ ID NO:16; CDRI varijabilno područje slabog lanca od SEQ ID NO:23; CDR2 varijabilno područje slabog lanca od SEQ ID NO:30; i CDR3 varijabilno područje slabog lanca od SEQ ID NOQO:37; ili
The compound according to claim 1 or 2, wherein: 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da:
processing three-dimensional data relating to a shape of at least said tooth and at least said part of said neighbouring tooth with a computer so as to determine said overlay (1); and processing said three-dimensional data to determine said predetermined part of tooth structure to be removed. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što postupak dodatno uključuje korake: računalne obrade trodimenzijskih podataka koji se odnose na oblik u najmanju ruku navedenog zuba i u najmanju ruku navedenog dijela navedenog zuba u susjedstvu radi određivanja navedene presvlake (1); i obrade navedenih trodimenzijskih podataka radi određivanja navedenog zadanog dijela zubne strukture kojeg treba ukloniti.
one or more solvents. 
(iii) jedno ili više otapala.
characterized in that said circuit for determining the wiring phase is located at said second location (200); and 
Sustav u skladu sa zahtjevom 1, naznačen time, da je navedeni krug za određivanje faznog vodiča smješten na navedenoj drugoj lokaciji (200); te
mixing the granules obtained in step b with a composition comprising a GLP-1 peptide; and 
miješanja granula dobivenih u koraku b s granulama dobivenim u koraku d; i
means for receiving the frame of the encoded digital audio signal; and 
(A) prijem okvira kodiranog digitalnog audio signala; i
The use of microcapsules with a polymeric wall according a suitable combination of claims 1 to 29 or produced according a suitable combination of claims 30 to 40 in an agrochemical formulation characterized in that the microencapsulated material is tebuconazole and/or propiconazole and/or ketoconazole and/or triadimenol and/or epoxiconazole, 
Mikrokapsule prema patentnim zahtjevima 1 do 27, naznačene time, što je mikroinkapsulirani materijal triazolni fungicid. Mikrokapsule prema patentnim zahtjevima 1 do 27, naznačene time, što je mikroinkapsulirani materijal tebukonazol i/ili propikonazol i/ili ketokonazol i/ili triadimenol i/ili epoksikonazol.
The method of claim 1, wherein said antigen or antigenic peptide in step a) is a bacterial or viral antigen or antigenic peptide from an organism selected from the group consisting of heartworm, Ehrlichia spp., Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia spp., Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplasma phagocytophilum, Anaplasma platys, feline leukemia virus, parvovirus, influenza A strain, influenza B strain, avian influenza virus, respiratory syncytial virus, Legionella, adenovirus, rotavirus, feline immunodeficiency virus, human immunodeficiency virus, and Group A Streptococcus. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni antigen ili antigeni peptid izt drugog detektora je iz organizma kojeg se bira iz skupine koju čine srčana glista, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia_ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplazma phagocytophilum, Anaplazma platys, virus mačje leukemije, parvovirus, soj A influence, soj B influence, virus ptičje influence, respiratorni sincicijski virus, Legionella, adenovirus, rotavirus, virus mačje imunodeficijencije, virus ljudske imunodeficijencije, te skupina A streptokoka.
in which X, R and R′ are as defined above, followed by 
(XII) u kojem su X, R i R' definirani gore.
to 90 %, preferably 10-40% by weight of binder, 
1 do 90 %, poželjnije 10-40 % masenog udjela vezujućeg sredstva,
In another preferred embodiment, following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity change is not more than 70 uS/cm per pH unit, and preferably not more than 50 uS/cm per pH unit. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da nakon dodavanja navedenog 2-((1-metilpropiljamino)etanola, promjena vodljivosti nije veća od 70 uS/em po jedinici pH, a poželjno nije veća od 50 uS/cm po jedinici pH.
The invention also encompasses methods where the compound is given in combination therapy. 
Spoj također može biti dan u kombiniranoj terapiji.
A suitable volume of the supernatant is removed and diluted to a suitable concentration. 
Odgovarajući volumen supernatanta je odstranjen i razrijeđen do odgovarajuće koncentracije.
A solution as claimed in claim 6 or 7comprising 0.1 to 1.0 g/L of sweetener, for example comprising one or both of acesulfame K and sucralose, and/or the solution comprises 1.0 to 10 g/L of flavouring, for example Orange Juice or Tropical Fruit flavour. 
Otopina u skladu s patentnim zahtjevom 6 ili 7, naznačena time što sadrži 0,1 do 1,0 g/l sladila, gdje primjerice sadrži jedno ili oboje od acesulfama K i sukraloze, i/ili što otopina sadrži 1,0 do 10 g/l arome, primjerice arome soka od naranče ili tropskog voća.
In some embodiments, said reacting of step (a) is carried out in the presence of activated molecular sieves. 
2. | Postupak sukladno zahtjevu 1, naznačen time, što se navedena reakcija iz koraka (e) provodi u prisutnosti Lewis15
Method for reading an electronic code formed by conductive code lines on a non-conductive surface, in which method 
Postupak za čitanje elektronskog koda, stvorenog pomoću provodljivih kodnih cijevi na neprovodljivoj plohi, pri čemu se u tom postupku
A compound according to claim 9, wherein R2 and R′2, together with the nitrogen atom to which they are linked, form a morpholinyl group optionally substituted by at least one substituent selected from the group consisting of: trifluoromethyl groups and alkyl groups. 
Spoj prema zahtjevu 9, naznačen time da R, i R',, zajedno sa atomom dušika na koji su spojeni, formiraju morfolinilnu skupinu proizvoljno supstituiranu sa barem jednim supstituentom odabranim iz skupine koja sadrži: trifluorometilne skupine i alkilne skupine.
The obtained solution is stirred for 15 minutes at 22 °C. Then the solvent is evaporated and the residue is mixed with 10 ml of acetonitrile. 
Dobivenu otopinu miješa se 15 minuta na 22 "C. Otapalo se zatim otpari, a ostatak pomiješa s 10 ml acetonitrila.
converting a cis / trans mixture of (+)-p-menth-2,8-dien-1-ol to trans-(-)-A9-tetrahydrocannabinol by reacting the cis / trans mixture of (+)-p-menth-2,8-dien-1-ol with olivetol in the presence of an acid catalyst and a dehydrating agent; 
konverzije cis/trans smjese (+)-p-ment-2,8-dien-1-ola u trans-(-)-A9-tertahidrokanabinol pomoću reakcije cis/trans smjese (+)-p-ment-2,8-dien-1-ola s olivetolom u prisutnosti kiselog katalizatora i sredstva za dehidraciju;
The resulting mixture was refluxed for 16 hours, cooled to room temperature, and 1.0 M NaOH (8 mL) was added. 
Dobivenu smjesu refluksira se 16 sati, ohladi na sobnu temperaturu, te se doda 1,0 M NaOH (8 ml).
A cylinder lock (1) according to claim 4, wherein the cylinder lock further comprises a buzzer box (17) connected to said connector (14). 
Cilindrična brava (1) prema zahtjevu 4, naznačena time da cilindrična brava nadalje sadrži kućište naprave za ispuštanje zvučnog signala (17) spojeno s navedenim konektorom (14).
A pharmaceutical composition comprising a compound of any one of claims 1-6, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time, da sadržava spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegov stereoizomer ili njegovu farmaceutski prihvatljivu sol, 1 farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
A method 600 for welding two or more conduit members 200, 300, the method 600 comprising: 
Postupak (600) za zavarivanje dva ili više elemenata voda (200,300), postupak (600) sastojeći se od:
A pharmaceutically composition comprising a therapeutically effective amount of the compound according to any one of claims 1 to 4. 
Farmaceutski sastav koji obuhvaća terapeutski djelotvornu količinu spoja prema patentnom zahtjevu 1.
The bispecific antibody for use of claim 27, wherein the cell proliferative disorder is a HER2-positive cancer. 
Bispecifično protutijelo za uporabu prema patentnom zahtjevu 19, naznačeno time, da se kod poremećaja stanične proliferacije radi o raku koji je pozitivan na HER2.
A method of diagnosing a condition or ailment of a patient comprising administering to said patient a porous substrate comprising at least one agent embedded within said pores of said substrate; wherein said pores are capped by at least one nucleic acid sequence having a locked conformation wherein said at least one agent is entrapped within said pores; said capping nucleic acid sequence is capable of forming a cleavage-prone conformation upon association with at least one first biomarker of said condition or ailment; thereby enabling said capping nucleic acid sequence to be cleaved by a biocatalyst and thereby upon cleavage allowing the release of said embedded at least one agent to the bodily fluid of said patient; and detecting said at least one agent in said bodily fluids of said patient. 
Postupak dijagnosticiranja stanja ili oboljenja kod pacijenta koja obuhavća davanje pacijentu poroznog supstrata koji obuhvaća barem jedan agens koji se nalazi u porama supstrata; pri čemu su pore preklopljene barem jednim nizom nukleinskih kiselina zaključane konformacije pri čemu je barem jedan agens sadržan unutar pora; niz preklopne nukleinske kiseline može formirati konformaciju sklonu cijepanju nakon spajanja s barem jednim prvim biomarkerom stanja ili oboljenja; omogućavajući time preklapanje nukleinske kiseline s biokatalizatorom i nakon cijepanja omogućavajući otpuštanje agensa u tjelesne tekućine pacijenta; određivanjem barem jednog agensa u tjelesnim tekućinama pacijenta.
the variable light chain comprises the variable light chain framework sequence from geAAH70335.1 and the CDRs from the VL chain of murine antibody HP1/2, wherein CDR1 comprises the sequence KASQSVTNDVA, CDR2 comprises the sequence YASNRYT and CDR3 comprises the sequence QQDYSSPYT, wherein: 
(b) varijabilni slabi lanac obuhvaća okvirnu sekvencu varijabilnog slabog lanca od IGKV4-1 i CDR-ove od VL-lanca mišjeg protutijela HP1/2, gdje CDR1 obuhvaća sekvencu KASQSVTNDVA, CDR2 obuhvaća sekvencu YASNRYT 1 CDR3 obuhvaća sekvencu QQDYSSPYT, pri čemu su:
2 g of product were obtained which, when purified by chromatography on silica gel (ethyl acetate/methanol gradient: 7:3/6:4), yielded 1.5 g of product (yield: 60%). 
Dobiveno je 2 g produkta koji je, kada je pročišćen kromatografijom na silikagelu (etil acetat/metanol gradijent: 7:3/6:4), dao 1,5 g produkta (prinos: 60 %).
The engraving of the body of composite permanent-magnetic material may be achieved by any way and method known in the art, by hand-engraving, by mechanical engraving machines, as well as by computer-controlled engraving stations which, furthermore, may produce the engraving either with the help of mechanical tools, or with gaseous or liquid jets of abrasives, or through laser-ablation, using e.g. 
Graviranje tijela od kompozitnih permanentno magnetskih materijala može se vršiti bilo kojim poznatim načinom ili postupkom, ručnim graviranjem, pomoću strojeva za mehaničko graviranje, kao 1 računalno nadziranim postajama za graviranje koje, osim toga, mogu izvršiti graviranje bilo mehaničkim alatima bilo mlazom plinskog ili tekućeg abraziva ili laserskim graviranjem putem npr.
For column chromatography silica gel of the type Kieselgel 60, 40-60 mesh ASTM was used. 
Za kolonsku kromatografiju se koristi silika gel tip Kiesgel 60, s 40-60 veličinom sita ASTM.
Management of hypertension being a long term therapy, use of wetting agents in the formulation of nebivolol need to be judiciously avoided. 
Kako je kontrola hipertenzije dugoročna terapija, uporabu tvari za vlaženje u formulacijama ncbivolola treba razumno izbjegavati.
a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and 
mutirani ptr gen, naznačen time, što mutirani ptr gen kodira Proteaza III protein sa smanjenom aktivnosti proteaze ili pak predstavlja isključeni mutirani ptr gen; i
Aggregated conformation prion protein obtainable by a process according to one of claims 1 to 9, characterized in that the aggregated conformation prion protein is of one amino acid sequence and has a homogenous aggregated state conformation. 
Prionski protein agregirane konformacije koji se može dobiti postupkom prema zahtjevima 1 do 11, naznačeno time da je prionski protein agregirane konformacije jedna sekvenca amino kiselina.
Such compositions may be prepared using conventional diluents or excipients and techniques known in the galenic art. 
Takovi sastavi se mogu proizvesti upotrebom uobičajenih sredstava za razređivanje ili pomoćnih sredstava i tehnika koje su poznate u galenskoj struci.
For example, such conditions include endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). 
Kao primjer, takva stanja uključuju endometriozu, fibroide maternice, bolest policističnih jajnika, hirzutizam, prerani pubertet, novotvorine ovisne o gonadnim steroidima, poput raka prostate, dojke, te jajnika, gonadotropne adenome hipofize, apneju u snu, sindrom iritabilnih crijeva, predmenstrualni sindrom, dobroćudnu hipertrofiju prostate, kontracepciju, te neplodnost (primjerice terapiju umjetnom reprodukcijom, poput oplodnje in vitro).
Comparative ET-743 % purity evolution of the new formulations stored at 40°C/70% RH during 3 months. 
razvoj ET-743 % čistoće novih oblika čuvanih na 40*%C/ 70% relativne vlažnosti u trajanju od 3